Latest News & Updates
Breaking News
4 hours ago
Vaibhavi M.
Other trending news you may like to read
FDA Accepts Roche’s NDA For Giredestrant Plus Everolimus In ESR1-Mutated ER-Positive Advanced Breast Cancer
FDA accepts Roche’s NDA for giredestrant plus everolimus in ESR1-mutated ER-positive advanced breast cancer.
Vaibhavi M.
AstraZeneca’s Calquence Plus Venetoclax Approved In US Based On Phase III AMPLIFY Trial Results, As First Fixed-Duration Oral Regimen For Chronic Lymphocytic Leukaemia (CLL) And Small Lymphocytic Lymphoma (SLL)
AstraZeneca’s Calquence plus venetoclax gains FDA approval as first fixed-duration oral regimen for CLL and SLL.
Vaibhavi M.
AndSmallLymphocyticLymphoma(SLL)20260221151321.png)
ImmunityBio Partners With Biopharma And Cigalah To Launch ANKTIVA In Saudi Arabia And Expand Across MENA, Secures Strategic Distribution Alliance
AstraZeneca’s Calquence plus venetoclax wins US approval as first fixed-duration oral regimen for CLL and SLL.
Vaibhavi M.
Outlook Therapeutics Partners With Mediconsult AG For Exclusive Swiss Distribution Of LYTENAVA™ (Bevacizumab Gamma) In Retina Disease Treatment
Outlook Therapeutics partners with Mediconsult for exclusive Swiss distribution of LYTENAVA™.
Simantini Singh Deo
InRetinaDiseaseTreatment20260220160128.png)